NMN/NR (Nicotinamide Mononucleotide/Riboside) Dosing for Black and African Ancestry Patients: What the Evidence Actually Shows

Why Ethnicity Matters for NAD+ Precursor Supplementation

NAD+ precursor therapy is not a one-size-fits-all intervention. Baseline NAD+ levels, enzymatic conversion efficiency, and the comorbidity burden that depletes NAD+ all differ across population groups. For patients of Black and African ancestry, three factors are particularly relevant: higher rates of hypertension and chronic kidney disease (CKD), a clinically meaningful prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency, and differences in inflammatory tone that affect NAMPT activity, the rate-limiting enzyme in the NAD+ salvage pathway.

None of these factors mandate a categorically lower or higher dose. They do, however, shape how a clinician should initiate, monitor, and titrate NMN or NR in this population.

The Baseline NAD+ Field in African Ancestry Populations

NAD+ declines with age in all adults. The rate and absolute level of that decline are modified by chronic inflammation, insulin resistance, and oxidative stress, all of which are statistically more prevalent in Black Americans due to well-documented social determinants of health and biological risk factors [1].

Chronic low-grade inflammation suppresses NAMPT, meaning the body's own capacity to regenerate NAD+ from nicotinamide is already partially impaired. Higher baseline inflammatory load could theoretically reduce conversion efficiency of oral NMN or NR into usable NAD+, though no head-to-head comparative trial has tested this hypothesis in ethnicity-stratified cohorts.

What "Dose Adjustment" Actually Means Here

In the absence of direct pharmacokinetic data stratified by race or ancestry, dose adjustment does not mean arbitrarily lowering the dose. It means:

• Starting at the lower end of the studied range (250 mg/day NMN or 300 mg/day NR)
• Screening for comorbidities that change the risk-benefit calculation (G6PD status, CKD stage, current antihypertensive regimen)
• Monitoring NAD+ metabolite markers (whole-blood NAD+, urinary N1-methylnicotinamide) at 8 to 12 weeks
• Adjusting upward only if the patient tolerates the starting dose and labs suggest sub-therapeutic conversion

The Yoshino 2021 Trial: Best Available Human Data

The most rigorous human NMN supplementation trial published to date is Yoshino et al., published in Science in 2021 [2]. This was a randomized, placebo-controlled, double-blind trial (N=25) in postmenopausal women with overweight or obesity and prediabetes. Participants received 250 mg/day of oral NMN for 10 weeks.

Key Findings

Skeletal-muscle NAD+ levels rose significantly in the NMN group. Insulin signaling in muscle improved, as measured by phosphorylation of AKT and mTOR targets. Whole-body insulin sensitivity, measured by hyperinsulinemic-euglycemic clamp, did not reach statistical significance at the group level (P<0.05 threshold not met for primary endpoint), but the muscle-specific metabolic effects were mechanistically meaningful.

The trial did not report subgroup data by race or ancestry. The cohort was recruited from Washington University in St. Louis, where the patient population is racially diverse, but the published paper does not break results out by ethnicity.

Why This Matters for African Ancestry Patients

Insulin resistance is significantly more prevalent in Black Americans. In NHANES 2017 to 2020 data, age-adjusted rates of type 2 diabetes were 12.1% in non-Hispanic Black adults vs. 7.4% in non-Hispanic White adults [3]. If NMN's primary measurable benefit in humans is improvement of muscle insulin signaling, Black patients with prediabetes or early type 2 diabetes represent a group with potentially the most to gain from optimizing this intervention. Starting at 250 mg/day and titrating based on glycemic markers over 10 to 12 weeks is a defensible clinical approach.

G6PD Deficiency: A Specific Pharmacogenomic Consideration

G6PD deficiency affects approximately 10 to 15% of males of African ancestry and a smaller proportion of females (heterozygous carriers may have intermediate enzyme activity) [4]. G6PD deficiency impairs the pentose phosphate pathway and reduces cellular NADPH, a distinct cofactor from NAD+ but produced from the same foundational niacin biochemistry.

Why This Is Relevant to NMN/NR

NMN and NR are converted to NAD+, not NADPH. The two pathways diverge at NAD+ kinase, which phosphorylates NAD+ to NADP+, and then at NADP+ reductase (which is the enzyme deficient in G6PD disease). High-dose niacin (nicotinic acid, a different NAD+ precursor) at doses above 1,500 mg/day has been associated with rare hemolytic episodes in G6PD-deficient individuals. NMN and NR are structurally distinct from nicotinic acid and are metabolized through the nicotinamide salvage pathway, not the de novo tryptophan pathway that requires G6PD.

No published case reports or trial data link NMN or NR supplementation to hemolysis in G6PD-deficient patients. The theoretical risk is low. Clinicians should still document G6PD status in patients of African ancestry before initiating doses above 500 mg/day NMN or 600 mg/day NR, and monitor a basic hemogram at 6 to 8 weeks if status is unknown.

Practical G6PD Screening Guidance

A standard quantitative G6PD enzyme assay (not the fluorescent spot test, which misses heterozygous females) confirms enzyme activity before high-dose supplementation. If the patient is G6PD-deficient, staying within the 250 mg/day NMN or 300 mg/day NR range is prudent until case-specific data emerge.

Hypertension and the Renin-Angiotensin System: Indirect Drug Interactions

Black patients have disproportionately high rates of hypertension (approximately 55 to 57% prevalence in Black adults, vs. 43% in non-Hispanic White adults) [5]. Standard antihypertensive therapy in this group often includes calcium channel blockers (CCBs) and thiazide diuretics as first-line agents, rather than ACE inhibitors or ARBs, because the physiologic phenotype of hypertension in Black patients frequently involves lower renin activity and greater sodium sensitivity.

How This Interacts with NMN/NR

NMN has shown vasodilatory properties in animal models by activating SIRT1 and increasing endothelial nitric oxide synthase (eNOS) expression. This mechanism could theoretically augment the antihypertensive effect of CCBs or thiazides. A small open-label human study (N=10) reported a modest reduction in diastolic blood pressure with 300 mg/day NR over 8 weeks, though the study was not powered for this endpoint [6].

Patients taking amlodipine, hydrochlorothiazide, or chlorthalidone should have blood pressure checked at 4 and 8 weeks after NMN/NR initiation. An additive antihypertensive effect is possible, though the magnitude is likely modest at standard supplement doses.

ACE inhibitors (lisinopril, enalapril) are used in Black patients primarily when a specific indication exists (CKD with proteinuria, heart failure with reduced ejection fraction). NMN's SIRT1-mediated effects on the kidney have not been characterized in patients on dual renin-angiotensin system blockade.

Thiazide Diuretics and NAD+ Metabolism

Thiazide-induced hypokalemia is more common at higher thiazide doses. Hypokalemia increases cellular oxidative stress, which in turn may accelerate NAD+ consumption via PARP activation. Patients on thiazides with low potassium (<3.5 mEq/L) may have a baseline NAD+ deficit that makes supplementation more relevant, but they also require electrolyte monitoring that is separate from and concurrent with any NAD+ precursor protocol.

Chronic Kidney Disease: Dose Consideration at the Organ Level

Black Americans develop kidney failure at approximately three times the rate of White Americans [7]. CKD itself is a state of accelerated NAD+ depletion. Kidney tissue is rich in NAMPT, and as nephrons are lost, systemic NAD+ regeneration capacity falls. Several research groups have proposed NMN supplementation as a potential renoprotective strategy, though no phase 3 trial in CKD patients has been completed.

Dosing in CKD Stages 3 to 4

NMN and NR are renally cleared as NAD+ metabolites, primarily N1-methylnicotinamide and 2-pyridone-5-carboxamide. In CKD stage 3 (eGFR 30 to 59 mL/min/1.73m²) and stage 4 (eGFR 15 to 29), these metabolites may accumulate. No formal pharmacokinetic study has been conducted in CKD patients for NMN or NR specifically.

A cautious approach:

• CKD stage 1 to 2 (eGFR >60): standard dosing (250 to 500 mg/day NMN or 300 to 1,000 mg/day NR)
• CKD stage 3: start at 250 mg/day NMN or 300 mg/day NR; check renal function and urinary metabolites at 8 weeks
• CKD stage 4: defer to nephrology before initiating; limited safety data
• CKD stage 5 / dialysis: no data; do not initiate without specialist oversight

Proteinuria and NAMPT

Experimental models show that NAMPT activity is reduced in the proximal tubule when proteinuria is present. This means patients with nephrotic-range proteinuria may have impaired conversion of NMN to NAD+ within kidney tissue specifically, even if systemic conversion is intact. Monitoring urinary NAD+ metabolites provides indirect evidence of whether supplementation is reaching the kidney compartment.

NAMPT Pharmacogenomics: A Closer Look

NAMPT (nicotinamide phosphoribosyltransferase) is the enzyme that converts nicotinamide into NMN intracellularly. It is the rate-limiting step in the salvage pathway and the enzyme through which oral NMN's systemic effects are thought to be mediated after conversion back to nicotinamide and re-phosphorylation.

Several single-nucleotide polymorphisms (SNPs) in the NAMPT gene have been identified. The rs9770242 variant has been associated with lower circulating eNAMPT (extracellular NAMPT) levels in population studies. Allele frequency distributions for NAMPT variants differ across ancestral populations, as cataloged in PharmGKB and gnomAD. Specifically, some variants associated with reduced NAMPT catalytic efficiency appear at higher frequencies in African ancestry populations in gnomAD v3 data, though functional validation in clinical supplementation trials is not yet available [8].

This is not a basis for altering dose empirically. It is a basis for measuring a patient's response at 10 to 12 weeks rather than assuming a standard dose produces a standard effect.

What Labs to Order

The following panel provides a practical assessment of NMN/NR response:

• Whole-blood NAD+ (available through specialty labs; reference range in adults approximately 20 to 40 nmol/mL, varying by lab)
• Urinary N1-methylnicotinamide (24-hour collection; rises with NAD+ repletion)
• Fasting insulin and HOMA-IR (primary metabolic outcome in the Yoshino trial framework)
• HbA1c (for patients with prediabetes or diabetes)
• Comprehensive metabolic panel (renal function, liver enzymes)
• CBC with differential (G6PD-relevant hemolytic screen at baseline and 8 weeks)

Comparing NMN and NR for African Ancestry Patients: Which Precursor?

NMN and NR enter the NAD+ salvage pathway at different points. NR is converted to NMN by NRK1/NRK2 (nicotinamide riboside kinases) before proceeding through NAMPT-independent steps. NMN may enter cells via the Slc12a8 transporter (confirmed in mouse intestine; human transporter status remains under investigation).

Absorption and Conversion Differences

A pharmacokinetic study by Trammell et al. (Cell Metabolism, 2016) in 12 healthy adults showed that oral NR at 1,000 mg raised whole-blood NAD+ by approximately 2.7-fold over 8 hours, with peak levels at 2 to 4 hours [9]. No comparable head-to-head pharmacokinetic trial has compared NMN vs. NR in the same subjects with ethnicity-stratified data.

The practical answer: for patients with CKD stage 3 or significant insulin resistance, NR has a slightly longer clinical track record at doses up to 1,000 mg/day and may be preferred for initial dosing because its metabolic pathway bypasses the Slc12a8 transporter uncertainty. For patients with confirmed cardiovascular benefit as the primary goal, NMN at 250 to 500 mg/day aligns more closely with the Yoshino trial design.

Cost and Adherence

NMN is generally more expensive per milligram than NR. For patients managing multiple chronic conditions, cost is a real adherence factor. 300 mg/day NR represents a lower-cost entry point with comparable NAD+-raising efficacy at that dose tier.

A Practical Titration Protocol for Clinicians

The following protocol applies to Black and African ancestry adults initiating NAD+ precursor therapy. It is not a replacement for individualized clinical judgment.

Week 0 (baseline labs):

• Whole-blood NAD+, fasting insulin, HbA1c, CMP, CBC, G6PD quantitative assay, blood pressure

Week 0 to 8 (initiation phase):

• NMN 250 mg/day oral once daily in the morning, or NR 300 mg/day
• Blood pressure check at week 4 for patients on antihypertensives
• No dose change during this phase

Week 8 to 10 (response assessment):

• Repeat whole-blood NAD+, fasting insulin, CMP, CBC
• If NAD+ has not risen above baseline by at least 30%, consider:
  • Checking NAMPT variant status (research-grade testing)
  • Increasing to NMN 500 mg/day or NR 600 mg/day
  • Assessing adherence and supplement quality (third-party tested products)

Week 12+ (maintenance or titration):

• If response is adequate: continue current dose with quarterly labs
• If response is inadequate and CKD stage <3: may titrate to NMN 500 to 1,000 mg/day or NR 1,000 mg/day with monthly CMP for 3 months
• If CKD stage 3 or above: do not exceed 500 mg/day NMN or 600 mg/day NR without nephrology co-management

The American Diabetes Association's 2024 Standards of Care state that "nutritional supplements are not recommended as treatment for diabetes or prediabetes," which means NMN/NR should be used as an adjunct to, not a replacement for, guideline-directed pharmacotherapy [10].

As HealthRX medical director Dr. Sarah Chen notes: "In patients of African ancestry with insulin resistance and elevated inflammatory markers, I treat NAD+ precursor therapy as a metabolic optimization tool that runs parallel to their medication regimen, not instead of it. I check a whole-blood NAD+ at baseline and again at 10 weeks. If we have not moved the needle by at least 25 to 30%, I look at NAMPT polymorphism data and reconsider the dose or the formulation."

Drug Interactions Specific to Common Medications in This Population

Several medications commonly prescribed in Black patients with hypertension, CKD, or diabetes have potential interactions with NAD+ precursors worth documenting.

Metformin

Metformin activates AMPK and raises cellular NAD+ indirectly via LKB1 signaling. Combining metformin with NMN or NR may produce additive NAD+-raising effects. No clinical trial has studied this combination. The theoretical interaction is likely beneficial rather than harmful, but it means NAD+ lab values in metformin-treated patients may already be partially normalized before supplementation begins, which could make the apparent "lift" from NMN/NR look smaller than in drug-naive patients.

Statins

Statin use is common in this population for cardiovascular risk reduction. Some statins inhibit CoQ10 synthesis via the mevalonate pathway. CoQ10 and NAD+ are both mitochondrial electron transport chain cofactors. Whether statin-induced CoQ10 depletion affects NMN/NR response is uncharacterized in clinical data.

SGLT2 Inhibitors

Empagliflozin and dapagliflozin are increasingly first-line in Black patients with CKD and type 2 diabetes because of their renal-protective trial data. SGLT2 inhibitors raise SIRT1 activity and may independently support NAD+ metabolism. The combination with NMN/NR is mechanistically logical and not contraindicated, but again, no RCT has tested it.